Hyperhomocyst(e)inemia impairs angiogenesis in a murine model of limb ischemia

Hyperhomocyst(e)inemia (HH) is an established independent risk factor for coronary, cerebral and peripheral vascular diseases. Recent studies have indicated that certain cardiovascular risk factors, including diabetes and hypercholesterolemia, impair expression of vascular endothelial growth factor (VEGF) and endogenous angiogenesis. In this study, we investigate the impact of moderate HH on angiogenesis and VEGF pathway in a mouse model of hindlimb ischemia. Upon induction of unilateral hindlimb ischemia, endogenous angiogenesis, expression of VEGF, and phosphorylation of the VEGF receptor Flk-1 were evaluated in mice heterozygous for a deletion of the cystathionine -synthase gene (CBS) and compared with those observed in CBS/mice. CBS/mice exhibit moderate HH, as demonstrated by measuring plasma total homocyst(e)ine (tHcy) levels, which were significantly higher in these animals compared with CBS/mice (4.77 0.82 vs 2.10 0.28, p 0.01). Twenty-eight days after induction of ischemia, hindlimb blood flow was significantly reduced in CBS/mice compared with CBS/animals (0.49 0.03, n 12 vs 0.71 0.09, n 10; p 0.05). In addition, there was a significant negative correlation between plasma homocyst(e)ine levels and the laser Doppler perfusion ratio in CBS/mice (p 0.0087, r 0.7171). While VEGF expression and Flk-1 phosphorylation were not impaired in the ischemic muscles of CBS/mice, phosphorylation of the endothelial cell survival factor Akt was significantly inhibited by homocyst(e)ine in a dose-dependent manner in human umbilical vein endothelial cell (HUVECs) in vitro. In conclusion, our findings demonstrate that endogenous angiogenesis is inversely related to plasma levels of homocyst(e)ine in genetically engineered, heterozygous mice with moderate HH. This impairment, however, is not dependent on reduced expression of VEGF or impaired phosphorylation of its receptor Flk-1. In contrast, our data suggest that impaired Akt phosphorylation mediates the impairment of angiogenesis associated with HH.

[1]  Douglas Losordo,et al.  Synergistic Effect of Bone Marrow Mobilization and Vascular Endothelial Growth Factor-2 Gene Therapy in Myocardial Ischemia , 2004, Circulation.

[2]  J. Loscalzo,et al.  L-Homocysteine and L-homocystine stereospecifically induce endothelial nitric oxide synthase-dependent lipid peroxidation in endothelial cells. , 2004, Free radical biology & medicine.

[3]  F. Tribl,et al.  Homocysteine strongly enhances metal-catalyzed LDL oxidation in the presence of cystine and cysteine. , 2003, Atherosclerosis.

[4]  D. Yamashiro,et al.  VEGF blocking therapy in the treatment of cancer , 2003, Expert opinion on biological therapy.

[5]  Napoleone Ferrara,et al.  Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. , 2002, Seminars in oncology.

[6]  I. Shiojima,et al.  Role of Akt Signaling in Vascular Homeostasis and Angiogenesis , 2002, Circulation research.

[7]  Hae-Young Lee,et al.  Differential Effects of Homocysteine on Porcine Endothelial and Vascular Smooth Muscle Cells , 2002, Journal of cardiovascular pharmacology.

[8]  K. Yamashita,et al.  Plasma level of homocysteine is inversely-associated with the development of collateral circulation in patients with single-vessel coronary artery disease. , 2002, Circulation journal : official journal of the Japanese Circulation Society.

[9]  J. Isner,et al.  VEGF gene transfer for diabetic neuropathy. , 2001, Human gene therapy.

[10]  J. Isner,et al.  HMG-CoA reductase inhibitor mobilizes bone marrow--derived endothelial progenitor cells. , 2001, The Journal of clinical investigation.

[11]  K. Yamashita,et al.  Homocysteine inhibits angiogenesis in vitro and in vivo. , 2001, Biochemical and biophysical research communications.

[12]  T. Murohara,et al.  Hyperhomocysteinemia Impairs Angiogenesis in Response to Hindlimb Ischemia , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[13]  T. Murohara,et al.  Hypercholesterolemia Inhibits Angiogenesis in Response to Hindlimb Ischemia: Nitric Oxide–Dependent Mechanism , 2000, Circulation.

[14]  Wenbiao Liu,et al.  Endothelial cell survival and apoptosis in the tumor vasculature , 2000, Apoptosis.

[15]  I. Shiojima,et al.  The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. , 2000, Nature Medicine.

[16]  J. Loscalzo,et al.  Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. , 2000, The Journal of clinical investigation.

[17]  B. Hultberg,et al.  Hypomethylation as a cause of homocysteine-induced cell damage in human cell lines. , 2000, Toxicology.

[18]  W. Sessa,et al.  Vascular endothelial growth factor-stimulated actin reorganization and migration of endothelial cells is regulated via the serine/threonine kinase Akt. , 2000, Circulation research.

[19]  P. Carmeliet.  Mechanisms of angiogenesis and arteriogenesis , 2000, Nature Medicine.

[20]  T. Finkel,et al.  Homocysteine accelerates endothelial cell senescence , 2000, FEBS letters.

[21]  I. Mcdowell,et al.  Homocysteine and endothelial dysfunction: a link with cardiovascular disease. , 2000, The Journal of nutrition.

[22]  M. Lewis,et al.  Homocysteine-induced inhibition of endothelium-dependent relaxation in rabbit aorta: role for superoxide anions. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[23]  A. Zeiher,et al.  Akt takes center stage in angiogenesis signaling. , 2000, Circulation research.

[24]  H. Jakubowski.  Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[25]  S. Yusuf,et al.  Homocyst(e)ine and Cardiovascular Disease: A Critical Review of the Epidemiologic Evidence , 1999, Annals of Internal Medicine.

[26]  T. Podor,et al.  Homocysteine-induced endoplasmic reticulum stress and growth arrest leads to specific changes in gene expression in human vascular endothelial cells. , 1999, Blood.

[27]  J. Isner,et al.  Gene therapy for myocardial angiogenesis. , 1999, American heart journal.

[28]  D. Borderie,et al.  Homocysteine decreases endothelin-1 production by cultured human endothelial cells. , 1999, European journal of biochemistry.

[29]  J. Isner,et al.  Impaired collateral vessel development associated with reduced expression of vascular endothelial growth factor in ApoE-/- mice. , 1999, Circulation.

[30]  W. Sessa,et al.  Regulation of endothelium-derived nitric oxide production by the protein kinase Akt , 1999, Nature.

[31]  Y. Fujio,et al.  Akt Mediates Cytoprotection of Endothelial Cells by Vascular Endothelial Growth Factor in an Anchorage-dependent Manner* , 1999, The Journal of Biological Chemistry.

[32]  S. Do,et al.  Akt Protein Kinase Enhances Human Telomerase Activity through Phosphorylation of Telomerase Reverse Transcriptase Subunit* , 1999, The Journal of Biological Chemistry.

[33]  J. Isner,et al.  Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. , 1999, The Journal of clinical investigation.

[34]  J. Isner,et al.  Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. , 1999, The American journal of pathology.

[35]  J. Isner,et al.  Age-dependent impairment of angiogenesis. , 1999, Circulation.

[36]  Vishva Dixit,et al.  Vascular Endothelial Growth Factor Regulates Endothelial Cell Survival through the Phosphatidylinositol 3′-Kinase/Akt Signal Transduction Pathway , 1998, The Journal of Biological Chemistry.

[37]  R. Man,et al.  Homocysteine stimulates the production and secretion of cholesterol in hepatic cells. , 1998, Biochimica et biophysica acta.

[38]  G. Vercellotti,et al.  Superoxide-dependent cerebrovascular effects of homocysteine. , 1998, The American journal of physiology.

[39]  J. Isner,et al.  Mouse model of angiogenesis. , 1998, The American journal of pathology.

[40]  J. Loscalzo,et al.  Stimulation of endothelial nitric oxide production by homocyst(e)ine. , 1997, Atherosclerosis.

[41]  J. Loscalzo,et al.  Homocyst(e)ine Decreases Bioavailable Nitric Oxide by a Mechanism Involving Glutathione Peroxidase* , 1997, The Journal of Biological Chemistry.

[42]  I. Mcdowell,et al.  Putative mechanisms for vascular damage by homocysteine , 1997, Journal of Inherited Metabolic Disease.

[43]  J. Loscalzo.  The oxidant stress of hyperhomocyst(e)inemia. , 1996, The Journal of clinical investigation.

[44]  N. Maeda,et al.  Mice deficient in cystathionine beta-synthase: animal models for mild and severe homocyst(e)inemia. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[45]  R. Schlegel,et al.  Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[46]  M. M. Rees,et al.  Homocysteinemia: association of a metabolic disorder with vascular disease and thrombosis. , 1993, Thrombosis research.

[47]  J. Sadler,et al.  Homocysteine inhibits von Willebrand factor processing and secretion by preventing transport from the endoplasmic reticulum. , 1993, Blood.

[48]  R. Clarke,et al.  Hyperhomocysteinemia: an independent risk factor for vascular disease. , 1991, The New England journal of medicine.

[49]  L. Taylor,et al.  Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. , 1989, Circulation.

[50]  R. Ross,et al.  Effect of sulfinpyrazone on homocysteine-induced endothelial injury and arteriosclerosis in baboons. , 1983, Circulation research.

[51]  G. Striker,et al.  Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. , 1980, Thrombosis research.

[52]  R. Wolfe,et al.  Homocysteine metabolism. , 1999, Annual review of nutrition.

[53]  蔡哲嘉,et al.  Inhibition of growth and p21ras methylation in vascular endothelial cells by homocysteine but not cysteine , 1997 .

[54]  J. Stamler,et al.  Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. , 1993, The Journal of clinical investigation.